These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 9743337

  • 1. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.
    Finney HM, Lawson AD, Bebbington CR, Weir AN.
    J Immunol; 1998 Sep 15; 161(6):2791-7. PubMed ID: 9743337
    [Abstract] [Full Text] [Related]

  • 2. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
    Moritz D, Groner B.
    Gene Ther; 1995 Oct 15; 2(8):539-46. PubMed ID: 8593604
    [Abstract] [Full Text] [Related]

  • 3. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
    Finney HM, Akbar AN, Lawson AD.
    J Immunol; 2004 Jan 01; 172(1):104-13. PubMed ID: 14688315
    [Abstract] [Full Text] [Related]

  • 4. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, Cerutti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK.
    Cancer Gene Ther; 2004 May 01; 11(5):371-9. PubMed ID: 15060573
    [Abstract] [Full Text] [Related]

  • 5. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.
    Alvarez-Vallina L, Hawkins RE.
    Eur J Immunol; 1996 Oct 01; 26(10):2304-9. PubMed ID: 8898938
    [Abstract] [Full Text] [Related]

  • 6. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
    Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM, Finer MH.
    J Immunol; 1998 Jul 01; 161(1):375-84. PubMed ID: 9647246
    [Abstract] [Full Text] [Related]

  • 7. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H.
    Cancer Res; 2001 Mar 01; 61(5):1976-82. PubMed ID: 11280755
    [Abstract] [Full Text] [Related]

  • 8. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N, Shibaguci H, Kuroki M, Yamada H, Kuroki M.
    Anticancer Res; 2010 Jul 01; 30(7):2731-8. PubMed ID: 20683006
    [Abstract] [Full Text] [Related]

  • 9. TCR subunit specificity of CTLA-4-mediated signaling.
    Siu E, Carreno BM, Madrenas J.
    J Leukoc Biol; 2003 Dec 01; 74(6):1102-7. PubMed ID: 12972512
    [Abstract] [Full Text] [Related]

  • 10. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M, Weth R, Wels WS.
    J Mol Biol; 2005 Mar 11; 346(5):1299-311. PubMed ID: 15713482
    [Abstract] [Full Text] [Related]

  • 11. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta.
    Annenkov A, Chernajovsky Y.
    Gene Ther; 2000 Apr 11; 7(8):714-22. PubMed ID: 10800096
    [Abstract] [Full Text] [Related]

  • 12. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z.
    Handb Exp Pharmacol; 2008 Apr 11; (181):329-42. PubMed ID: 18071952
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes.
    Alvarez-Vallina L, Agha-Mohammadi S, Hawkins RE, Russell SJ.
    J Immunol; 1997 Dec 15; 159(12):5889-95. PubMed ID: 9550385
    [Abstract] [Full Text] [Related]

  • 14. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP.
    Clin Cancer Res; 1999 Dec 15; 5(12):3928-41. PubMed ID: 10632322
    [Abstract] [Full Text] [Related]

  • 15. Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes.
    Lustgarten J, Eshhar Z.
    Eur J Immunol; 1995 Oct 15; 25(10):2985-91. PubMed ID: 7589102
    [Abstract] [Full Text] [Related]

  • 16. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
    Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B.
    Clin Cancer Res; 1996 Jun 15; 2(6):1001-8. PubMed ID: 9816261
    [Abstract] [Full Text] [Related]

  • 17. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.
    Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, Tsokos GC.
    Arthritis Rheum; 2003 Jul 15; 48(7):1948-55. PubMed ID: 12847689
    [Abstract] [Full Text] [Related]

  • 18. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
    Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z.
    J Immunol; 1993 Dec 01; 151(11):6577-82. PubMed ID: 7902379
    [Abstract] [Full Text] [Related]

  • 19. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes.
    Tran AC, Zhang D, Byrn R, Roberts MR.
    J Immunol; 1995 Jul 15; 155(2):1000-9. PubMed ID: 7608531
    [Abstract] [Full Text] [Related]

  • 20. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ.
    Cancer Res; 2006 Nov 15; 66(22):10995-1004. PubMed ID: 17108138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.